Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28152768 | 0.91 | KMT2A (0.39) | KMT2AFABP5FABP7EPHX2MDM4 | |
| SCHEMBL9709460 | 0.84 | CYP1A2 (0.43) | KMT2ACYP1A2TSHR | |
| SCHEMBL4906912 | 0.82 | CYP1A2 (0.41) | KMT2ACYP1A2TSHR | |
| SCHEMBL6947332 | 0.82 | TSHR (0.40) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL10435405 | 0.81 | POLB (0.39) | KMT2ACYP1A2TSHR | |
| SCHEMBL30889906 | 0.81 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30272536 | 0.81 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL5863799 | 0.81 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15939517 | 0.81 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL9015851 | 0.80 | TSHR (0.42) | KMT2ACYP1A2TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023143496-A1 | METHOD FOR SYNTHESIZING INTERMEDIATE OF IMIDAZO[1,2-B] PYRIDAZINE COMPOUND | 和记黄埔医药（上海）有限公司 | 2023-08-03 | — | — | WO | claimed |
| US-20230235328-A1 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | Nexoligo Co., Ltd. (KR) | 2023-07-27 | — | — | US | claimed |
| EP-3225627-B9 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | UNIV NORTHWEST (CN) | 2022-01-05 | — | — | EP | claimed |
| WO-2021235662-A1 | HYALURONIC ACID-BASED HYDROGEL USING PEPTIDE CROSSLINKING AGENT, AND METHOD FOR PRODUCING SAME | 주식회사 차메디텍 | 2021-11-25 | — | — | WO | claimed |
| EP-3225627-B1 | TRIPEPTIDE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | UNIV NORTHWEST (CN) | 2021-11-03 | — | — | EP | claimed |
| EP-3428287-B1 | CONFORMATIONALLY-PREORGANIZED, MINIPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS | UNIV CARNEGIE MELLON (US) | 2021-03-24 | — | — | EP | claimed |
| EP-3556435-B1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) | 2020-10-28 | — | — | EP | claimed |
| EP-3556435-A1 | CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE | Beijing Showby Pharmaceutical Co., Ltd. (CN) | 2019-10-23 | — | — | EP | claimed |
| EP-2694683-B1 | CONFORMATIONALLY-PREORGANIZED, MiniPEG-CONTAINING GAMMA-PEPTIDE NUCLEIC ACIDS | UNIV CARNEGIE MELLON (US) | 2019-08-28 | — | — | EP | claimed |
| WO-2018038436-A1 | DIAMINE COMPOUND AND METHOD FOR PRODUCING SAME | 주식회사 엘지화학 | 2018-03-01 | — | — | WO | claimed |
| EP-0934250-A2 | PROCESS TO PREPARE PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1999-08-11 | — | — | EP | claimed |
| WO-1999015540-A2 | METHOD FOR PRODUCING A PENTOPYRANOSYL NUCLEOSIDE | AVENTIS RESEARCH & TECHNOLOGIES GMBH & CO KG (DE) | 1999-04-01 | — | — | WO | claimed |
| WO-1999014238-A1 | PROCESS FOR THE PREPARATION OF CALCITONIN | HYUNDAI PHARM. IND. CO., LTD. (KR) | 1999-03-25 | — | — | WO | claimed |
| EP-0832279-A1 | AN ASSAY REAGENT AND A METHOD OF MAKING AND USING THE ASSAY REAGENT | Coulter International Corp. (US) | 1998-04-01 | — | — | EP | claimed |
| US-5733719-A | REACTING A COMPOUND CONTAINING LEAVING GROUP SELECTED FROM AMINO ACIDS, PEPTIDES, LIPIDS, NUCLEOSIDES ETC, AND A BLOCKING AGENT WITH AN AGENT TO FORM INTERMEDIATE COMPLEX, REACTING INTERMEDIATE WITH INDICATOR, DEBLOCKING, PURIFYING | COULTER CORPORATION (US) | 1998-03-31 | — | — | US | claimed |
| WO-1998009601-A2 | PROCESS TO PREPARE PHARMACEUTICAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| WO-1996036729-A1 | AN ASSAY REAGENT AND A METHOD OF MAKING AND USING THE ASSAY REAGENT | COULTER INTERNATIONAL CORP. (US) | 1996-11-21 | — | — | WO | claimed |
| EP-0650595-A4 | UNIVERSAL STANDARD REAGENTS, METHOD OF PREPARING SAME AND USE THEREOF. | PATCHORNIK ZIPORA (IL) | 1996-08-21 | — | — | EP | claimed |
| EP-0650595-A1 | UNIVERSAL STANDARD REAGENTS, METHOD OF PREPARING SAME AND USE THEREOF | PATCHORNIK, Zipora (IL) | 1995-05-03 | — | — | EP | claimed |
| WO-1994001771-A1 | UNIVERSAL STANDARD REAGENTS, METHOD OF PREPARING SAME AND USE THEREOF | PATCHORNIK, ZIPORA (IL) | 1994-01-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235328-A1 | NOVEL MORPHOLINO OLIGONUCLEOTIDE DERIVATIVES | RNGTT, MPO, RNMT | KMT2A 2236/4885FABP5 2270/4885FABP7 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.